Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vigna E, Martino EA, Cassin R, D Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Monti P, Menichini P, Olivieri J, Cutrona G, Rossi D, Cuneo A, Di Raimondo F, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: galimberti s. Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3. Am J Hematol. 2021. PMID: 33878220 Free article. No abstract available.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: galimberti s. Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24. Am J Hematol. 2021. PMID: 33580969 Free article. No abstract available.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Bossio S, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Recchia AG, Rossi FM, Zucchetto A, Al-Janazreh H, Martino EA, Vigna E, Tripepi G, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Jaksic O, Olivieri J, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Morabito F, et al. Among authors: galimberti s. Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25. Am J Hematol. 2021. PMID: 33989438 Free article. No abstract available.
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Luminari S, et al. Among authors: galimberti s. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. J Clin Oncol. 2022. PMID: 34709880 Clinical Trial.
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, Cavo M, Arcaini L, Trentin L, Cattaneo C, Derenzini E, Fracchiolla NS, Marchesi F, Scattolin A, Billio A, Bocchia M, Massaia M, Gambacorti-Passerini C, Mauro FR, Gentile M, Mohamed S, Della Porta MG, Coviello E, Cilloni D, Visani G, Federici AB, Tisi MC, Cudillo L, Galimberti S, Gherlinzoni F, Pagano L, Guidetti A, Bertù L, Corradini P, Passamonti F, Visco C. Merli M, et al. Among authors: galimberti s. Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25. Hematol Oncol. 2023. PMID: 36265128 Free PMC article. Clinical Trial.
A new digital droplet PCR method for looking at epigenetics in diffuse large B-cell lymphomas: The role of BMI1, EZH2, and USP22 genes.
Lusci Gemignani A, Papotti R, Bomben R, Gattei V, Pozzi S, Donati V, Bettelli S, Forti E, Mansueto G, Di Napoli A, Cox MC, Flenghi L, Rossi P, Volpe G, Dardanis D, Bono C, Guerrini F, Morganti R, Sacchi S, Galimberti S. Lusci Gemignani A, et al. Among authors: galimberti s. Int J Lab Hematol. 2024 Sep 10. doi: 10.1111/ijlh.14363. Online ahead of print. Int J Lab Hematol. 2024. PMID: 39255961
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S, Marasca R, Caracciolo F, Fazzi R, Papineschi F, Benedetti E, Guerrini F, Morabito F, Oliva E, Di Renzo N, Federico M, Petrini M, Torelli G; For GISL. Galimberti S, et al. Bone Marrow Transplant. 2002 Apr;29(7):581-7. doi: 10.1038/sj.bmt.1703422. Bone Marrow Transplant. 2002. PMID: 11979307 Free article.
466 results